Conference abstract · 14 Jun 2018
Conference abstractPublished 8 Oct 2015
Design and synthesis of gyrase and topoisomerase IV inhibitors
J S S University, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bacterial resistance to antibiotics has long been recognized, and it is today considered to be a serious worldwide health problem. As a result of resistance, some bacterial infections are either difficult to treat with antibiotics or even untreatable. This problem has become especially serious with the recent development of multiple drug resistance in certain strains of bacteria, such as Streptococcus pneumoniae (sp), mycobacterium tuberculosis, and enterococcus. As a result of the need to combat drug-resistant bacteria and the increasing failure of the available drugs, there has been a resurgent interest in discovering new antibiotics. One attractive strategy for developing new antibiotics is to inhibit DNA gyrase and topoisomerase IV, bacterial enzymes necessary for DNA replication, and therefore, necessary for bacterial cell growth and division. Type II topoisomerases catalyse the inter-conversion of DNA topoisomers by transporting one DNA segment through another bacteria encode two type II topoisomerase enzymes, DNA gyrase and DNA topoisomerase IV. DNA gyrase controls DNA supercoiling and relieves topological stress. Topoisomerase IV decatenates daughter chromosomes following replication and can also relax supercoiled DNA. Bacterial type II topoisomerases form a heterotetrameric complex composed of two subunits. DNA gyrase forms an A2B2 complex comprised of GyrA and GyrB, whereas topoisomerase IV forms a C2E2 complex comprised of ParC and ParE. As bacterial resistance to antibiotics has become an important public health problem, there is a continuing need to develop newer and more potent antibiotics. More particularly, there is a need for antibiotics that represent a new class of compounds not previously used to treat bacterial infection. Compounds that target the ATP binding sites in both the GyrB (gyrase) and parE (topoisomerase IV) subunits would be useful for treating various bacterial infections.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 30 Apr 2015
New tricks for an old dog: discovery, synthesis, in vitro and in vivo antitumor evaluation as well as docking studies of novel rutaecarpine derivatives as Topoisomerase I inhibitors
Conference abstract
Design, synthesis and biological evaluations of Antitumor 6,11-dihydro-indolizino[8,7-b]indole-1,2-diyl) dimethanol having multi-functions, inhibition of Topoisomerase I/II and DNA cross-linking
Conference abstract · 18 Mar 2019
Drug repurposing approach to identify novel inhibitors for targeting DNA gyrase in Mycobacterium tuberculosis: insights into mechanism and drug action
Research article · 9 Oct 2018
Design and Synthesis of Heterocyclic Curcumin Analogues as Filarial Topoisomerase II Inhibitors
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Janarthanan Thathan”
- BylineArticles whose byline prints “Mohammed Afzal Azam”

